Prospective Population Study on Candidemia in Spain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

730 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-03-31

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to describe the epidemiology of fungal blood infections in Spain (with emphasis on the incidence, fungal species distribution and antifungal susceptibility). The study is to be performed in five big cities which represent different geographic areas: Barcelona, Bilbao, Madrid, Sevilla and Valencia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Epidemiological Study in Subjects With Vulvovaginal Candidiases

NCT03064789

Vulvovaginal Candidiases

COMPLETED

Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis

NCT00036179

Candidiasis

COMPLETED PHASE2

Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis

NCT02248506

Candidiasis, Vulvovaginal

COMPLETED PHASE4

PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.

NCT03121235

Aspergillosis, Invasive Pulmonary

COMPLETED

A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common

NCT00002325

Mycoses HIV Infections Coccidioidomycosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fungemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fungemia

Patients with a fungal isolate from a blood culture

Non intervention

Intervention Type OTHER

Non interventional study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non intervention

Non interventional study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Fungal isolate obtained from blood sample

Exclusion Criteria

* None

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Manuel Cuenca, MD, PhD

Role: STUDY_DIRECTOR

Instituto de Salud Carlos III

Belen Padilla, MD

Role: STUDY_DIRECTOR

Hospital Gregorio Marañon

Isabel Ruiz, MD

Role: STUDY_DIRECTOR

Hospital Vall d'Hebron

Jose Garnacho-Montero, MD

Role: STUDY_DIRECTOR

Hospital Virgen del Rocio

Review the countries where the study has at least one active or historical site.

Spain

References

Explore related publications, articles, or registry entries linked to this study.

Puig-Asensio M, Fernandez-Ruiz M, Aguado JM, Merino P, Lora-Pablos D, Guinea J, Martin-Davila P, Cuenca-Estrella M, Almirante B. Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections. Antimicrob Agents Chemother. 2016 May 23;60(6):3291-300. doi: 10.1128/AAC.00195-16. Print 2016 Jun.

Reference Type DERIVED

PMID: 26976872 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GEMICOMED-GEIH 0109

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection

NCT00388167 COMPLETED

Study of FK463 for the Treatment of Invasive Aspergillosis

NCT00036166 COMPLETED PHASE2

Clinical Impact of Fungal Domestic Environmental Exposure on COPD Patients

NCT02318524 COMPLETED

Diagnostic Study of Combined Biomnarker Testing in Bronchoalveolar Lavage Samples of Immunocompromised Patients

NCT01695512 UNKNOWN

Effectiveness and Efficiency of a Voriconazole Preemptive Genotyping Strategy

NCT04238884 UNKNOWN PHASE4

Registry of Patients Treated With Systemic Mold-Active Triazoles

NCT03066011 COMPLETED

Anidulafungin in Patients With Hematologic Malignancies

NCT01053884 TERMINATED PHASE2

Research of New Serological Markers for the Diagnosis and Monitoring of Candidaemia in Hospitalized Patients

NCT05720728 COMPLETED

A Laboratory-based Surveillance Study of Candida Bloodstream Infections (MK-0991-093)

NCT01174147 COMPLETED

Historical Control Study of Refractory IFI or Patients Intolerant to Standard Antifungal Therapy in Patients With Invasive Fungal Infections (Study P02387)

NCT00230243 COMPLETED

Seifem Surveillance of Antifungal Combination Therapy In Hematologic Italian Centers

NCT00906633 COMPLETED

Changing Patterns of Candida Infections in Urban Medical Centers

NCT00366223 COMPLETED

Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant

NCT00445952 COMPLETED

Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm

NCT06582186 NOT_YET_RECRUITING PHASE4

Prophylaxis With Caspofungin in High-Risk Liver Transplantation

NCT00333645 UNKNOWN PHASE2

Invasive Fungal Infections Surveillance Initiative

NCT00177944 COMPLETED

Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy

NCT00002038 COMPLETED NA

Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis

NCT00002010 COMPLETED NA

Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients

NCT03067350 COMPLETED

Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)

NCT00704951 WITHDRAWN

Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole

NCT03572049 COMPLETED PHASE2/PHASE3

Studies of Disorders With Increased Susceptibility to Fungal Infections

NCT01222741 RECRUITING

Liver Transplant European Study Into the Prevention of Fungal Infection

NCT01058174 COMPLETED PHASE3

FungiScope - A Global Emerging Fungal Infection Registry

NCT01731353 RECRUITING

A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.

NCT04550936 COMPLETED

Prospective Population Study on Candidemia in Spain

Study Results

Basic Information

Brief Summary

Related Clinical Trials

Epidemiological Study in Subjects With Vulvovaginal Candidiases

Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis

Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis

PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.

A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common

Detailed Description

Conditions

Study Design

Study Groups

Fungemia

Non intervention

Interventions

Non intervention

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

Astellas Pharma Inc

Gilead Sciences

Merck Sharp & Dohme LLC

Pfizer

Fundacion SEIMC-GESIDA

Responsible Party

Principal Investigators

Manuel Cuenca, MD, PhD

Belen Padilla, MD

Isabel Ruiz, MD

Jose Garnacho-Montero, MD

Locations

Hospital del Mar

Hospital de Barcelona

Hospital Vall d'Hebrón

Hospital Clinic i Provincial

Hospital de la Santa Creu i Sant Pau

Hospital Sant Joan de Dèu

Hospital Fundación de Alcorcón

Hospital de la Princesa

Hospital Gregorio Marañon

Hospital del Niño Jesús

Hospital Infanta Leonor

Hospital Ramon y Cajal

Fundación Jiménez Díaz

Hospital Clínico San Carlos

Hospital 12 de Octubre

Hospital La Paz

Hospital Puerta de Hierro Majadahonda

Hospital San Juan de Dios del Aljarafe

Hospital Virgen de Macarena

Clínica Sagrado Corazón

Hospital Virgen del Rocío

Hospital Nuestra Señora de Valme

Hospital La Fe

Hospital Clínico de Valencia

Hospital General de Valencia

Hospital Doctor Peset

Hospital de Cruces

Hospital de Basurto

Hospital de Galdakao-Usansolo

Countries

References

Other Identifiers

GEMICOMED-GEIH 0109

More Related Trials